{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:01:31Z","timestamp":1782208891092,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2022A23"],"award-info":[{"award-number":["LC2022A23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01806-x","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:42:40Z","timestamp":1752576160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MRI-based texture analysis for the evaluation of the response to neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Haoran","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoduo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"3","key":"1806_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1806_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.mayocp.2015.12.017","volume":"91","author":"S Marur","year":"2016","unstructured":"Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386\u201396.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 10","key":"1806_CR3","doi-asserted-by":"publisher","first-page":"x173","DOI":"10.1093\/annonc\/mds299","volume":"23","author":"BJ Braakhuis","year":"2012","unstructured":"Braakhuis BJ, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol. 2012;23(Suppl 10):x173\u2013177.","journal-title":"Ann Oncol"},{"issue":"7","key":"1806_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable Local-Regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(7):1345\u201352.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1806_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent Squamous-Cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"10212","key":"1806_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr., Psyrri A, Bast\u00e9 N, Neupane P, Bratland \u00c5, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"5","key":"1806_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s12094-023-03342-y","volume":"26","author":"S Yan","year":"2024","unstructured":"Yan S, Liu L, Zhang X, Wei L, Jiang W, Gao X, Yang A, Liu X, Chen W, Chen Y, et al. Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma. Clin Transl Oncol. 2024;26(5):1192\u2013202.","journal-title":"Clin Transl Oncol"},{"issue":"15","key":"1806_CR8","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu B, Peng G, Xiao G, Huang J, Ding Q, Yang C, Xiong X, Ma H, Shi L, et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: A Single-Arm phase 2 clinical trial. Clin Cancer Res. 2022;28(15):3268\u201376.","journal-title":"Clin Cancer Res"},{"key":"1806_CR9","doi-asserted-by":"publisher","first-page":"1282629","DOI":"10.3389\/fimmu.2023.1282629","volume":"14","author":"WJ Wu","year":"2023","unstructured":"Wu WJ, Liu Q, An PG, Wang L, Zhang JY, Chen Y, Zhang T, Zhang J. Neoadjuvant Tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study. Front Immunol. 2023;14:1282629.","journal-title":"Front Immunol"},{"issue":"1","key":"1806_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","volume":"41","author":"X Huang","year":"2022","unstructured":"Huang X, Liu Q, Zhong G, Peng Y, Liu Y, Liang L, Hong H, Feng W, Yang S, Zhang Y, et al. Neoadjuvant Toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ib clinical trial. J Exp Clin Cancer Res. 2022;41(1):300.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"1806_CR11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","volume":"25","author":"G Wan","year":"2024","unstructured":"Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, Rajeh A, Seo J, Rashdan H, Zubiri L, et al. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol. 2024;25(8):1053\u201369.","journal-title":"Lancet Oncol"},{"key":"1806_CR12","doi-asserted-by":"crossref","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer 2024, 12(7).","DOI":"10.1136\/jitc-2023-008591"},{"issue":"12","key":"1806_CR13","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1007\/s00262-023-03557-6","volume":"72","author":"P Xu","year":"2023","unstructured":"Xu P, Fang Q, Zhao Z, Cao F, Wu D, Liu X. Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity. Cancer Immunol Immunother. 2023;72(12):4209\u201319.","journal-title":"Cancer Immunol Immunother"},{"key":"1806_CR14","doi-asserted-by":"crossref","unstructured":"Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer 2020, 8(1).","DOI":"10.1136\/jitc-2019-000146"},{"key":"1806_CR15","doi-asserted-by":"publisher","first-page":"153605","DOI":"10.1016\/j.prp.2021.153605","volume":"226","author":"G Paolino","year":"2021","unstructured":"Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, et al. PD-L1 evaluation in head and neck squamous cell carcinoma: insights regarding specimens, heterogeneity and therapy. Pathol Res Pract. 2021;226:153605.","journal-title":"Pathol Res Pract"},{"key":"1806_CR16","doi-asserted-by":"publisher","first-page":"108337","DOI":"10.1016\/j.compbiomed.2024.108337","volume":"173","author":"Z Bo","year":"2024","unstructured":"Bo Z, Song J, He Q, Chen B, Chen Z, Xie X, Shu D, Chen K, Wang Y, Chen G. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma. Comput Biol Med. 2024;173:108337.","journal-title":"Comput Biol Med"},{"issue":"2","key":"1806_CR17","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, Djelouah M, Journo G, Menet E, Cabel L, et al. Multiparametric MRI and radiomics for the prediction of HER2-Zero, -Low, and -Positive breast cancers. Radiology. 2023;308(2):e222646.","journal-title":"Radiology"},{"issue":"1","key":"1806_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18383\/j.tom.2018.00038","volume":"5","author":"EJ Ulrich","year":"2019","unstructured":"Ulrich EJ, Menda Y, Boles Ponto LL, Anderson CM, Smith BJ, Sunderland JJ, Graham MM, Buatti JM, Beichel RR. FLT PET radiomics for response prediction to chemoradiation therapy in head and neck squamous cell Cancer. Tomography. 2019;5(1):161\u20139.","journal-title":"Tomography"},{"key":"1806_CR19","doi-asserted-by":"publisher","first-page":"708398","DOI":"10.3389\/fonc.2021.708398","volume":"11","author":"A Rodrigues","year":"2021","unstructured":"Rodrigues A, Loman K, Nawrocki J, Hoang JK, Chang Z, Mowery YM, Oyekunle T, Niedzwiecki D, Brizel DM, Craciunescu O. Establishing ADC-Based histogram and texture features for early Treatment-Induced changes in head and neck squamous cell carcinoma. Front Oncol. 2021;11:708398.","journal-title":"Front Oncol"},{"issue":"6","key":"1806_CR20","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1007\/s00330-022-09362-6","volume":"33","author":"L Miao","year":"2023","unstructured":"Miao L, Cao Y, Zuo L, Zhang H, Guo C, Yang Z, Shi Z, Jiang J, Wang S, Li Y, et al. Predicting pathological complete response of neoadjuvant radiotherapy and targeted therapy for soft tissue sarcoma by whole-tumor texture analysis of multisequence MRI imaging. Eur Radiol. 2023;33(6):3984\u201394.","journal-title":"Eur Radiol"},{"issue":"2","key":"1806_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jmri.26589","volume":"50","author":"A Cromb\u00e9","year":"2019","unstructured":"Cromb\u00e9 A, P\u00e9rier C, Kind M, De Senneville BD, Le Loarer F, Italiano A, Buy X, Saut O. T(2) -based MRI Delta-radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy. J Magn Reson Imaging. 2019;50(2):497\u2013510.","journal-title":"J Magn Reson Imaging"},{"issue":"Suppl 1","key":"1806_CR22","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.acra.2020.10.026","volume":"28","author":"L Wan","year":"2021","unstructured":"Wan L, Peng W, Zou S, Ye F, Geng Y, Ouyang H, Zhao X, Zhang H. MRI-based delta-radiomics are predictive of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Acad Radiol. 2021;28(Suppl 1):S95\u2013104.","journal-title":"Acad Radiol"},{"key":"1806_CR23","doi-asserted-by":"publisher","first-page":"824509","DOI":"10.3389\/fonc.2022.824509","volume":"12","author":"Y Xi","year":"2022","unstructured":"Xi Y, Ge X, Ji H, Wang L, Duan S, Chen H, Wang M, Hu H, Jiang F, Ding Z. Prediction of response to induction chemotherapy plus concurrent chemoradiotherapy for nasopharyngeal carcinoma based on MRI radiomics and Delta radiomics: A Two-Center retrospective study. Front Oncol. 2022;12:824509.","journal-title":"Front Oncol"},{"key":"1806_CR24","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.eclinm.2023.101899","volume":"58","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhu T, Zhang X, Li W, Zheng X, Cheng M, Ji F, Zhang L, Yang C, Wu Z, et al. Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study. EClinicalMedicine. 2023;58:101899.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"1806_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cac2.12480","volume":"43","author":"S Ren","year":"2023","unstructured":"Ren S, Lan T, Wu F, Chen S, Jiang X, Huo C, Li Z, Xie S, Wu D, Wang R, et al. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Commun (Lond). 2023;43(10):1143\u201363.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"1806_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1806_CR27","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1007\/s00330-020-07612-z","volume":"31","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Yu X, Ouyang H, Zhang J, Chen S, Xie L, Zhao X. Whole-tumor texture model based on diffusion kurtosis imaging for assessing cervical cancer: a preliminary study. Eur Radiol. 2021;31(8):5576\u201385.","journal-title":"Eur Radiol"},{"issue":"1","key":"1806_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","volume":"15","author":"D Wu","year":"2024","unstructured":"Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H, Li Y, Su Y, Lu L, Chen L, et al. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat Commun. 2024;15(1):2177.","journal-title":"Nat Commun"},{"key":"1806_CR29","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.oraloncology.2024.106918","volume":"156","author":"X Zhao","year":"2024","unstructured":"Zhao X, Zhou Y, Peng G, Wen L, Hong X, Hu Y, Wu B, Liu X, Zhang Z, Xiao G, et al. Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma. Oral Oncol. 2024;156:106918.","journal-title":"Oral Oncol"},{"key":"1806_CR30","doi-asserted-by":"crossref","unstructured":"Alberti A, Lorini L, Ravanelli M, Perri F, Vinches M, Rondi P, Romani C, Bossi P. New challenges in evaluating outcomes after immunotherapy in recurrent and\/or metastatic head and neck squamous cell carcinoma. Vaccines (Basel) 2022, 10(6).","DOI":"10.3390\/vaccines10060885"},{"issue":"21","key":"1806_CR31","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/cncr.34930","volume":"129","author":"SA Patel","year":"2023","unstructured":"Patel SA, Gibson MK, Deal A, Sheth S, Heiling H, Johnson SM, Douglas K, Flores M, Blumberg J, Lumley C, et al. A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer. 2023;129(21):3381\u20139.","journal-title":"Cancer"},{"issue":"1","key":"1806_CR32","doi-asserted-by":"publisher","first-page":"1844403","DOI":"10.1080\/2162402X.2020.1844403","volume":"9","author":"D Evrard","year":"2020","unstructured":"Evrard D, Hourseau M, Couvelard A, Paradis V, Gauthier H, Raymond E, Halimi C, Barry B, Faivre S. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. Oncoimmunology. 2020;9(1):1844403.","journal-title":"Oncoimmunology"},{"key":"1806_CR33","doi-asserted-by":"publisher","first-page":"920021","DOI":"10.3389\/fimmu.2022.920021","volume":"13","author":"X Zhao","year":"2022","unstructured":"Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, Hou R, Ma W, Liu D, Zheng J, et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 Blockades. Front Immunol. 2022;13:920021.","journal-title":"Front Immunol"},{"issue":"10","key":"1806_CR34","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s11547-021-01389-x","volume":"126","author":"C Scapicchio","year":"2021","unstructured":"Scapicchio C, Gabelloni M, Barucci A, Cioni D, Saba L, Neri E. A deep look into radiomics. Radiol Med. 2021;126(10):1296\u2013311.","journal-title":"Radiol Med"},{"issue":"12","key":"1806_CR35","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2014.512","volume":"111","author":"N Just","year":"2014","unstructured":"Just N. Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer. 2014;111(12):2205\u201313.","journal-title":"Br J Cancer"},{"issue":"2","key":"1806_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jmri.25156","volume":"44","author":"J Liu","year":"2016","unstructured":"Liu J, Mao Y, Li Z, Zhang D, Zhang Z, Hao S, Li B. Use of texture analysis based on contrast-enhanced MRI to predict treatment response to chemoradiotherapy in nasopharyngeal carcinoma. J Magn Reson Imaging. 2016;44(2):445\u201355.","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"1806_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdz108","volume":"30","author":"S Trebeschi","year":"2019","unstructured":"Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, C\u01celin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30(6):998\u20131004.","journal-title":"Ann Oncol"},{"issue":"1","key":"1806_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-024-00560-6","volume":"12","author":"D Chen","year":"2024","unstructured":"Chen D, Zhang R, Huang X, Ji C, Xia W, Qi Y, Yang X, Lin L, Wang J, Cheng H, et al. MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma. Biomark Res. 2024;12(1):14.","journal-title":"Biomark Res"},{"issue":"6","key":"1806_CR39","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00234-024-03339-6","volume":"66","author":"H Liu","year":"2024","unstructured":"Liu H, Zhu C, Wang X, Chen X, Li Z, Xian J. Prediction of pathological complete response in locally advanced head and neck squamous cell carcinoma treated with neoadjuvant chemo-immunotherapy using volumetric multisequence MRI histogram analysis. Neuroradiology. 2024;66(6):919\u201329.","journal-title":"Neuroradiology"},{"key":"1806_CR40","doi-asserted-by":"publisher","first-page":"109638","DOI":"10.1016\/j.radonc.2023.109638","volume":"183","author":"M Bologna","year":"2023","unstructured":"Bologna M, Corino V, Cavalieri S, Calareso G, Gazzani SE, Poli T, Ravanelli M, Mattavelli D, de Graaf P, Nauta I, et al. Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset. Radiother Oncol. 2023;183:109638.","journal-title":"Radiother Oncol"},{"key":"1806_CR41","doi-asserted-by":"crossref","unstructured":"Zhang MH, Cao D, Ginat DT. Radiomic model predicts lymph node response to induction chemotherapy in locally advanced head and neck Cancer. Diagnostics (Basel) 2021, 11(4).","DOI":"10.3390\/diagnostics11040588"},{"issue":"6","key":"1806_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s11547-023-01644-3","volume":"128","author":"J Zhong","year":"2023","unstructured":"Zhong J, Frood R, McWilliam A, Davey A, Shortall J, Swinton M, Hulson O, West CM, Buckley D, Brown S, et al. Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings. Radiol Med. 2023;128(6):765\u201374.","journal-title":"Radiol Med"},{"issue":"7","key":"1806_CR43","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.acra.2021.08.026","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang KY, Jia HD, Fang X, Lin TT, Wei C, Qian LT, Dong JN. Feasibility of predicting pelvic lymph node metastasis based on IVIM-DWI and texture parameters of the primary lesion and lymph nodes in patients with cervical Cancer. Acad Radiol. 2022;29(7):1048\u201357.","journal-title":"Acad Radiol"},{"issue":"11","key":"1806_CR44","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/0284186X.2017.1346382","volume":"56","author":"M Bogowicz","year":"2017","unstructured":"Bogowicz M, Riesterer O, Stark LS, Studer G, Unkelbach J, Guckenberger M, Tanadini-Lang S. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncol. 2017;56(11):1531\u20136.","journal-title":"Acta Oncol"},{"key":"1806_CR45","doi-asserted-by":"publisher","first-page":"734872","DOI":"10.3389\/fonc.2021.734872","volume":"11","author":"K Hellwig","year":"2021","unstructured":"Hellwig K, Ellmann S, Eckstein M, Wiesmueller M, Rutzner S, Semrau S, Frey B, Gaipl US, Gostian AO, Hartmann A, et al. Predictive value of multiparametric MRI for response to Single-Cycle induction Chemo-Immunotherapy in locally advanced head and neck squamous cell carcinoma. Front Oncol. 2021;11:734872.","journal-title":"Front Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:43:23Z","timestamp":1757249003000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01806-x","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the tenets of the Declaration of Helsinki. The ethics committee of National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved this retrospective study and waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}